Budesonide in the treatment of inflammatory bowel disease |
| |
Authors: | Silverman Jason Otley Anthony |
| |
Institution: | Department of Pediatrics, Dalhousie University and IWK Health Centre, Halifax, NS, Canada. |
| |
Abstract: | Inflammatory bowel disease, including Crohn's disease and ulcerative colitis, features recurrent episodes of inflammation of the GI tract. The treatment of inflammatory bowel disease is aimed at breaking the cycle of relapsing and remitting inflammation by inducing and maintaining remission. Systemically active conventional corticosteroids have long played a role in the induction of remission in both Crohn's disease and ulcerative colitis, however, their long-term use can lead to adverse systemic effects. Budesonide, a synthetic steroid, has potent local anti-inflammatory effects and limited systemic bioavailability making it an appealing therapeutic option. Ulcerative colitis with predominantly distal disease may be treated with topical budesonide, however, novel oral controlled-release formulations have also been developed to allow for treatment of the entire colon. This article summarizes the use of budesonide in the management of inflammatory bowel disease. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|